CLINICAL_TRIALS
trial_result
· 2018-10-03
Clinical Trial Update: Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus [Phase 3]
Summary
Open-label extension study of Epratuzumab in systemic lupus erythematosus completed; results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED | Results posted: 2018-10-03